• March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
  • October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
  • April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
  • March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
  • October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
  • March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctorsPrimary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
  • March 21, 2014 - Identification of Novel, Efficacious F508del‐CFTR Correctors to Treat Cystic Fibrosis
  • October 14, 2013 - Next generation F508del CFTR correctors using a YFP based high throughput screening assay
  • October 14, 2013 - Intestinal Current Measurement to Assess Modulation of F508del-CFTR Function
  • October 14, 2013 - A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity
More posters

Home

N30 Pharmaceuticals

N30 Pharmaceuticals Boulder Colorado headquarters

N30 Pharmaceuticals

Founded in 2007 with headquarters in Boulder, Colorado.

N30 Pharma is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis.

As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO.

N30 Pharma has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease.

Cystic Fibrosis

  • Reduced levels of GSNO are associated with cystic fibrosis
  • GSNO, through nitric oxide signaling, is integral to the normal function of CFTR, the transmembrane regulator protein that is defective in cystic fibrosis
  • Anti-inflammatory effects of GSNOR inhibitors relevant to cystic fibrosis include decreased NFκB activation, neutrophilic infiltration, and elastase-mediated lung injury
  • Lead compound, N6022, has completed Phase 1 testing in healthy subjects, a proof of concept study in asthma, and is poised to enter clinical trials in cystic fibrosis in the first quarter of 2013